Valion Bio, Inc. (NASDAQ:VBIO)
| Market Cap | 9.11M-97.2% |
| Revenue (ttm) | -156.00K-139.8% |
| Net Income | -18.75M-195.7% |
| EPS | -4.53+24.1% |
| Shares Out | 4.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,456.551 |
| Open | 2.07 |
| Previous Close | 2.19 |
| Day's Range | 2.07 - 2.22 |
| 52-Week Range | 2.05 - 78.75 |
| Beta | 1.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About VBIO
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$VBIO stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VBIO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VBIO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VBIO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
VBIO Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Property and equipment, net | $12.34M | 57.90% |
| Goodwill | $3.46M | 16.22% |
| Licensed technology, net | $2.24M | 10.52% |
| Cash and cash equivalents | $2.11M | 9.89% |
| Inventory, net | $750.00K | 3.52% |
| Restricted cash | $368.00K | 1.73% |
| Change in fair value of derivative liability | $47.00K | 0.22% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New VBIO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VBIO from public contracts
Source: USAspending.gov
VBIO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VBIO’s recent data — informational, not investment advice